KaloBios Pharma (KBIO) Announces Filing of 10-Q, 10-K for 2015
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
KaloBios Pharmaceuticals, Inc. (OTC: KBIO) announced the filing with the U.S. Securities and Exchange Commission (SEC) of the company’s Form 10-Q for the three and nine months ended September 30, 2015, and its Form 10-K for the fiscal year ended December 31, 2015.
The filings mark an important step towards the achievement of one of the company’s key near-term goals of regaining compliance with periodic reporting requirements of the SEC and to seek relisting on a national securities exchange.
“Our momentum continues to build due to our intense focus on executing our strategic priorities,” said Cameron Durrant, MD, KaloBios chairman and CEO. “We intend to be back in compliance with our filings as expeditiously as possible, as we also work to strengthen our financial position and accelerate our pipeline programs.”
KaloBios emerged from bankruptcy on June 30, 2016, with new management and a transformational strategy, including the Responsible Pricing Model.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bill Barrett Corporation (BBG) Entered Confidentiality Agreement with Bonanza Creek Energy (BCEI) Pertaining to BCEI's Chapter 11 Proceeding
- Aqua America (WTR) Offers FY17 Guidance
- AEP Industries (AEPI) Shareholders Vote in Favor of Berry Plastics (BERY) Merger Plan
Create E-mail Alert Related CategoriesCorporate News, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!